HomeCompareBDX vs NDAQ

BDX vs NDAQ: Dividend Comparison 2026

BDX yields 2.27% · NDAQ yields 1.29%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NDAQ wins by $114.4K in total portfolio value· pulled ahead in Year 3
10 years
BDX
BDX
● Live price
2.27%
Share price
$154.69
Annual div
$3.51
5Y div CAGR
13.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.9K
Annual income
$1,058.14
Full BDX calculator →
NDAQ
NDAQ
● Live price
1.29%
Share price
$83.52
Annual div
$1.08
5Y div CAGR
62.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.3K
Annual income
$64,247.81
Full NDAQ calculator →

Portfolio growth — BDX vs NDAQ

📍 NDAQ pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBDXNDAQ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BDX + NDAQ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BDX pays
NDAQ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BDX
Annual income on $10K today (after 15% tax)
$192.91/yr
After 10yr DRIP, annual income (after tax)
$899.42/yr
NDAQ
Annual income on $10K today (after 15% tax)
$109.91/yr
After 10yr DRIP, annual income (after tax)
$54,610.64/yr
At 15% tax rate, NDAQ beats the other by $53,711.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BDX + NDAQ for your $10,000?

BDX: 50%NDAQ: 50%
100% NDAQ50/50100% BDX
Portfolio after 10yr
$84.1K
Annual income
$32,652.97/yr
Blended yield
38.82%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NDAQ right now

BDX
Analyst Ratings
16
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$193.80
+25.3% upside vs current
Range: $170.00 — $215.00
Altman Z
2.1
Piotroski
8/9
NDAQ
Analyst Ratings
23
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$113.60
+36.0% upside vs current
Range: $108.00 — $120.00
Altman Z
2.5
Piotroski
9/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BDX buys
0
NDAQ buys
0
No recent congressional trades found for BDX or NDAQ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBDXNDAQ
Forward yield2.27%1.29%
Annual dividend / share$3.51$1.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR13.5%62.3%
Portfolio after 10y$26.9K$141.3K
Annual income after 10y$1,058.14$64,247.81
Total dividends collected$5.7K$114.0K
Payment frequencyquarterlyquarterly
SectorHealthcareFinancials
Analyst consensusBuyBuy
Analyst price target$193.80$113.60

Year-by-year: BDX vs NDAQ ($10,000, DRIP)

YearBDX PortfolioBDX Income/yrNDAQ PortfolioNDAQ Income/yrGap
1$10,958$257.59$10,910$209.87+$48.00BDX
2$12,024$299.40$12,021$347.30+$3.00BDX
3← crossover$13,214$348.50$13,443$580.44$229.00NDAQ
4$14,545$406.26$15,368$984.57$823.00NDAQ
5$16,038$474.35$18,151$1,707.33$2.1KNDAQ
6$17,715$554.80$22,481$3,058.70$4.8KNDAQ
7$19,606$650.06$29,800$5,746.07$10.2KNDAQ
8$21,741$763.12$43,440$11,553.61$21.7KNDAQ
9$24,161$897.64$72,027$25,545.86$47.9KNDAQ
10$26,910$1,058.14$141,316$64,247.81$114.4KNDAQ

BDX vs NDAQ: Complete Analysis 2026

BDXHealthcare

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

Full BDX Calculator →

NDAQFinancials

Nasdaq, Inc. operates as a technology company that serves capital markets and other industries worldwide. The Market Technology segment includes anti financial crime technology business, which offers Nasdaq Trade Surveillance, a SaaS solution for brokers and other market participants to assist them in complying with market rules, regulations, and internal market surveillance policies; Nasdaq Automated Investigator, a cloud-deployed anti-money laundering tool; and Verafin, a SaaS technology provider of anti-financial crime management solutions. This segment also handles assets, such as cash equities, equity derivatives, currencies, interest-bearing securities, commodities, energy products, and digital currencies. The Investment Intelligence segment sells and distributes historical and real-time market data; develops and licenses Nasdaq-branded indexes and financial products; and provides investment insights and workflow solutions. The Corporate Platforms segment operates listing platforms; and offers investor relations intelligence and governance solutions. As of December 31, 2021, it had 4,178 companies listed securities on The Nasdaq Stock Market, including 1,632 listings on The Nasdaq Global Select Market; 1,169 on The Nasdaq Global Market; and 1,377 on The Nasdaq Capital Market. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income and commodities trading and clearing, and trade management service businesses. This segment operates various exchanges and other marketplace facilities across various asset classes, which include derivatives, commodities, cash equity, debt, structured products, and exchange traded products; and provides broker, clearing, settlement, and central depository services. The company was formerly known as The NASDAQ OMX Group, Inc. and changed its name to Nasdaq, Inc. in September 2015. Nasdaq, Inc. was founded in 1971 and is headquartered in New York, New York.

Full NDAQ Calculator →
📬

Get this BDX vs NDAQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BDX vs SCHDBDX vs JEPIBDX vs OBDX vs KOBDX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.